Polyrizon Ltd., a biotechnology company focused on developing intranasal products, has announced promising preclinical results for its PL-14 Allergy Blocker as part of its proprietary Capture & Contain platform. Conducted in collaboration with the University of Parma, the study assessed the product's performance in delivering targeted deposition to the nasal vestibule, a key site for allergen contact. The results, presented using a validated silicone-based human nasal cast, showed over 60% deposition in the nasal vestibule. This targeted delivery supports PL-14's potential as a barrier-forming treatment for allergic rhinitis. Polyrizon plans to continue preclinical validation and move toward clinical trials to further develop its C&C platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.